Poolbeg Pharma granted extension to PUSU Deadline

On 2 January 2025, HOOKIPA Pharma Inc. (Nasdaq: HOOK) and Poolbeg Pharma plc (LON:POLB) announced that they have entered into non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg (the “Possible Offer” and the “2.4 Announcement”, respectively) to create a strong clinical-stage biopharmaceutical company focused on developing and commercialising innovative medicines for critical unmet medical needs, with a special focus on next-generation immunotherapies for the treatment of cancer and other serious diseases. Since then, the respective HOOKIPA and Poolbeg management teams have been holding extensive positive discussions and working constructively through the due diligence process, which is ongoing. The 2.4 Announcement stated that, in accordance with Rule 2.6(a) of the Code, HOOKIPA is required, by not later than 5.00 p.m. (London time) on 30 January 2025, to do one of the following: (i) announce a firm intention to make an offer for Poolbeg in accordance with Rule 2.7 of the Code; or (ii) announce that it does not intend to make an offer for Poolbeg, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies.

In order to allow further time for the diligence exercise and discussions to be completed, the Board of Poolbeg has requested that the Panel extend the PUSU Deadline in accordance with Rule 2.6(c) of the Code.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

AI-powered drug discovery is changing the future of medicine

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for